Press release
Central Nervous System Disorder Drugs Market to See Incredible Growth During 2019
Report Overview @ https://www.transparencymarketresearch.com/central-nervous-system-disorder-drugs.html
It is reported by Parkinson’s disease Foundation that as of now 7-10 million people are affected with Parkinson’s disease across the globe. These diseases are generally caused by neurodegeneration, autoimmune disorders, trauma, tumors and vascular disorders.
The market for CNS disorders is categorized into three segments namely psychiatry, neurology and pain drugs market. Psychiatry drugs market is further segmented into anxiety, depression, bipolar disorders, schizophrenia and ADHD (attention deficit hyperactivity disorder).
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1475
Neurology drugs market is divided into migraine, epilepsy, Parkinson’s disease, multiple sclerosis, narcolepsy and and Alzheimer’s disease. Pain management drugs market segment comprises of drugs used to treat pain associated with CNS disorders. Among these psychiatry segment holds the largest share accounting for more than 40% followed by neurology and pain segment.
Rapidly increasing geriatric population base resulting in an elevated incidence levels of CNS disorders such as Alzheimer’s disease, Parkinson’s disease, schizophrenia and multiple disorders is one of the key factors driving the growth of the market for CNS disorders.. Currently, there is no drug to cure Alzheimer’s disease, the available medicines only treat the severity of symptoms and improve the quality of life to some extent. That is why companies such as Eli Lilly, Baxter International and Novartis AG are investing heavily in research and development in order to accelerate the treatment of Alzheimer’s disease.
Geographically, North America holds the largest share of the total market of CNS disorders followed by Europe and Asia-Pacific. Asia-Pacific is projected to grow at a CAGR more than other regions on account of high prevalence of diseases such as epilepsy, Parkinson’s disease and Alzheimer’s disease. As of 2012, WHO (world health organization) suggests that around 50 million people are suffering from epilepsy worldwide, most of them (approximately 80%) belong to developing nations.
Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1475<ype=S
Some of the key players operating in the market for CNS disorders are Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis AG, Sanofi, Merck & Co., Abbott Laboratories, Eli Lilly, UCB, Bristol-Meyers Squibb Co. and Astellas Pharma, Inc.
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Central Nervous System Disorder Drugs Market to See Incredible Growth During 2019 here
News-ID: 875656 • Views: …
More Releases from Transparency Market Research
Cold Milling Machine Market to Reach US$ 3.9 Bn by 2034, Expanding at 5.4% CAGR …
The cold milling machine market was valued at US$ 2.2 billion in 2023 and is projected to reach US$ 3.9 billion by the end of 2034, expanding at a steady CAGR of 5.4% from 2024 to 2034. Market growth is being fueled by rising investments in road construction, infrastructure development, and highway rehabilitation projects across both developed and emerging economies.
Access key findings and insights from our Report in this sample…
Overhead Cranes Market Trends and Forecast 2034: Smart Lifting Solutions, Region …
The global overhead cranes market is entering a steady and technology-driven growth phase, supported by rising industrialization, infrastructure investments, and automation-led transformation in material handling. Manufacturing expansion in developing economies, coupled with large-scale construction of roads, bridges, ports, and industrial facilities, continues to generate sustained demand for overhead cranes. At the same time, the integration of IoT, smart sensors, and automated controls is redefining crane performance standards by improving safety,…
Flexible Packaging Paper Market to be Worth USD 65.2 Bn by 2029 - By Kraft, Glas …
The global Flexible Packaging Paper Market was valued at US$ 47.5 Bn in 2021 and is projected to reach US$ 65.2 Bn by the end of 2029, expanding at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2029. The steady expansion of this market reflects the increasing global preference for sustainable, lightweight, and cost-efficient packaging solutions across multiple industries. The growing shift away from rigid packaging toward…
Insect Repellent Apparel Market Outlook 2034: Rising Demand for Functional, Prot …
The global insect repellent apparel market was valued at US$ 812.2 million in 2023 and is projected to reach US$ 1.6 billion by the end of 2034, growing at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2034. The market is witnessing steady expansion due to increasing awareness of vector-borne diseases, rising outdoor recreational activities, growing adoption of functional textiles, and continuous innovation in fabric treatment technologies.
Insect…
More Releases for Parkinson’s
Parkinson’s Disease Treatment Market 2021 | Detailed Report
Parkinson’s Disease Treatment Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Parkinsons Disease Treatment Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5024082
The report provides a comprehensive analysis of company profiles listed below:
- Teva
- Roche
- Prothena
- Acorda…
Parkinson’s Disease Treatment Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Parkinson’s Disease Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Parkinson’s Disease Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Parkinson’s Disease Treatment with respect…
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds…
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that…
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports.
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,…
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent.
Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial…
